Crimson Blot Syndrome is a paralysis-inducing condition associated with dry, reddened skin on the hands, arms, legs, and feet. Patients often describe a tingling sensation as the condition progresses. Early treatment is crucial for preventing the partial and complete paralysis associated with later stages of Crimson Blot Syndrome.
Treatment A is a recently approved treatment for Crimson Blot Syndrome. It has few known side effects but is associated with a 1 in 4 (25%) chance of severe rash. Patients typically experience this rash after 4 years of treatment with Treatment A but report rashes as late as 7 years after treatment. The risk of Paralysis when taking Treatment A has been shown to be as low as 25% (or 1 in 4 patients). Patients taking Treatment A also tend to develop Paralysis at much later stages of the condition with an 8 year average onset.
Treatment B has been used for several years to treat Crimson Blot Syndrome. It has a known history of increased risk of headaches with 1 out of 2 (50%) patients reporting increased headaches starting 3 years after beginning Treatment B. These headaches continue while the patients continue to take Treatment B. Treatment B has been shown to successfully delay the onset of Paralysis to an average of 6 years. Treatment B is associated with a higher risk of Paralysis (3 of 4 patients or 75%)
Treatment C is a once per day medication for Crimson Blot Syndrome associated with a lower risk of paralysis (35%). 3 of 4 (75%) Patients chosing Treatment C report increased or excessive sweating when first starting to take Treatment C. These side effects are reported only for the first few years with the latest reports 5 years after treatment with Treatment C begins. Most patients taking Treatment C remain healthy but the minority of patients develop Paralysis after an average of 4 years.
| Treatment | Advantages | Disadvantages |
|---|---|---|
| Treatment A |
|
|
| Treatment B |
|
|
| Treatment C |
|
|
Treatment Explorer